Recent extensive investigations into the intricate inter-play between PARP and DDR pathways have illuminated the significance of HRR deficiency and the potential of PARPi to exploit synthetic lethality in GC, making PARP a promising therapeutic target in the field. This evidence concerns the gene PARP1 and gastric cancer.